Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

161. Young children with ADHD are at increased risk of depression and suicidal behaviour in adolescence

and suicidal behaviour in adolescence Statistics from Altmetric.com Question Question Are young children with attention-deficit/hyperactivity disorder (ADHD) at increased risk for depression and suicidal ideation and attempts during adolescence? Population 125 children with DSM -IV ADHD at 4–6 years of age and a control group of 123 children without ADHD who were matched to the children with ADHD for gender, race/ethnicity and age, and were from similar neighbourhoods and schools. Exclusions Children (...) not living with their biological mothers, pervasive developmental disorder, intellectual disability or seizure disorder. Setting Chicago, Illinois and Pittsburgh, Pennsylvania, USA; time period not stated. Prognostic factors DSM -IV ADHD diagnosis at age 4–6 years made using the Diagnostic Interview Schedule for Children completed by the primary care giver and the teacher-completed Disruptive Behavior Disorders Rating Scale. Children were considered to have ADHD if they met diagnostic criteria according

2011 Evidence-Based Mental Health

162. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. (Abstract)

Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. The effects of a restricted elimination diet in children with attention-deficit hyperactivity disorder (ADHD) have mainly been investigated in selected subgroups of patients. We aimed to investigate whether there is a connection between diet and behaviour in an unselected group of children.The Impact of Nutrition on Children with ADHD (...) (INCA) study was a randomised controlled trial that consisted of an open-label phase with masked measurements followed by a double-blind crossover phase. Patients in the Netherlands and Belgium were enrolled via announcements in medical health centres and through media announcements. Randomisation in both phases was individually done by random sampling. In the open-label phase (first phase), children aged 4-8 years who were diagnosed with ADHD were randomly assigned to 5 weeks of a restricted

2011 Lancet Controlled trial quality: predicted high

163. [Effect of vitamins, minerals and other dietary supplements on mental health symptoms for people with ADHD, anxiety disorders, bipolar disorder or depression]

of mental disorders. •The documentation was too limited to draw any conclusions about the effect of inositol, folate, and vitamin B-6. •The documentation was too limited to draw any conclusions about adverse events from dietary supplements. •Several of the systematic reviews were published more than six years ago. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anxiety; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Depression; Dietary Supplements; Mental (...) [Effect of vitamins, minerals and other dietary supplements on mental health symptoms for people with ADHD, anxiety disorders, bipolar disorder or depression] Effekten av vitaminer, mineraler og andre kosttilskudd på psykiske symptomer hos personer med ADHD, angstlidelser, bipolar lidelse eller depresjon [Effect of vitamins, minerals and other dietary supplements on mental health symptoms for people with ADHD, anxiety disorders, bipolar disorder or depression] Effekten av vitaminer, mineraler

2011 Health Technology Assessment (HTA) Database.

164. Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment

deficit hyperactivity disorder (ADHD); (2) compare long-term effectiveness and adverse events of interventions for ADHD among persons of all ages; and (3) describe how identification and treatment for ADHD vary by geography, time period, provider type, and sociodemographic characteristics, compared with endemic prevalence. Authors' conclusions The SOE for PBT as the first-line intervention for improved behavior among preschoolers at risk for ADHD was high, while the SOE for methylphenidate (...) Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all

2011 Health Technology Assessment (HTA) Database.

165. Provision of brief paediatrician training and computer-assisted medication management does not improve symptoms in children with ADHD

in children with ADHD Article Text Therapeutics Provision of brief paediatrician training and computer-assisted medication management does not improve symptoms in children with ADHD Statistics from Altmetric.com Question Question Does provision of brief physician training and computer-assisted medicine management improve symptoms in children with attention-deficit hyperactivity disorder (ADHD) compared with treatment as usual (TAU)? Patients 270 children (77% boys; age range 5.9–11.11 years; mean age 8.2 (...) years) with ADHD diagnosed according to DSM-V criteria (combined type: 49%, hyperactive/impulsive type: 9.8% and inattentive type: 41.2%) and attending participating paediatric practices. Main exclusions: taking an antipsychotic or medication for ADHD in the previous 2 months; intolerance to stimulants or taking medication not compatible with stimulants; not living with their primary care giver for the previous 6 months; an IQ<70 or attending classes for children with intellectual disabilities

2011 Evidence-Based Mental Health

166. Siblings of adolescents with ADHD who themselves have ADHD are more likely to have psychiatric comorbidities than are unaffected siblings or controls without ADHD

are more likely to have psychiatric comorbidities than are unaffected siblings or controls without ADHD Article Text Prevalence Siblings of adolescents with ADHD who themselves have ADHD are more likely to have psychiatric comorbidities than are unaffected siblings or controls without ADHD Statistics from Altmetric.com Question Question What is the rate of psychiatric comorbidities in adolescents with attention-deficit hyperactivity disorder (ADHD) and their siblings? Population 136 adolescent probands (...) (mean age 12.8 years, 85% male) with ADHD (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria), 136 siblings of the probands (selected sibling closest in age to the proband if more than one sibling; mean age 11.5 years for ADHD-affected siblings and 13.1 years for unaffected siblings) and 136 control participants who were age- and sex-matched to the proband and did not have a diagnosis of ADHD (mean age 12.4 years). Adolescents with autistic spectrum disorders

2011 Evidence-Based Mental Health

167. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

168. Adding 8 weeks of behavioural therapy to atomoxetine does not improve classroom behaviour in children with ADHD

therapy to atomoxetine does not improve classroom behaviour in children with ADHD Statistics from Altmetric.com Question Question Is the combination of atomoxetine and behavioural therapy (BT) more effective than drug treatment alone for children with attention-deficit hyperactivity disorder (ADHD)? Patients 56 children (45 boys) aged 6–12 years with DSM-IV-TR ADHD of moderate severity (mean Clinical Global Impressions–Severity of Illness Score 4.3). Exclusions : history of seizures, contraindication (...) Adding 8 weeks of behavioural therapy to atomoxetine does not improve classroom behaviour in children with ADHD Adding 8 weeks of behavioural therapy to atomoxetine does not improve classroom behaviour in children with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username

2011 Evidence-Based Mental Health

169. Review: childhood ADHD increases the risk of nicotine use in adolescence and alcohol use in young adulthood

of nicotine use in adolescence and alcohol use in young adulthood Statistics from Altmetric.com Question Question Does childhood attention-deficit/hyperactivity disorder (ADHD) increase the risk of substance use disorders (SUDs) in adolescence and young adulthood? Outcomes Persistent substance use, abuse or dependence meeting DSM-IV TR (Diagnostic and Statistical Manual, Fourth Edition, Text Revision) criteria for SUDs. Single substance categories included alcohol, cannabis, cigarettes, tobacco (...) children (≤12 years) with and without ADHD (DSM-III, DSM-III-R, DSM-IV criteria or DSM-II hyperkinetic disorder) and following participants to a mean age of 18 years or older. Inclusion criteria for nicotine use were extended to include adolescents aged 14–16 years because of the few eligible studies. A single reviewer selected studies and assessed internal validity with a second reviewer appraising a random sample. Studies of historical cohorts or … Request Permissions If you wish to reuse any or all

2011 Evidence-Based Mental Health

170. Guidelines and recommendations for ADHD in children and adolescents

medications had exceeded $35 million (or 77% of total expenditures on ADHD medications) by public drug plans in Canada. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Practice Guidelines as Topics Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs (...) Guidelines and recommendations for ADHD in children and adolescents Guidelines and recommendations for ADHD in children and adolescents Guidelines and recommendations for ADHD in children and adolescents CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Guidelines and recommendations for ADHD in children and adolescents. Ottawa

2011 Health Technology Assessment (HTA) Database.

171. OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD

RE, Mestas R et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. Journal of Clinical Psychiatry 2007; 68: 93-101. Stein MA et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003; 112: 404. Swanson J et al. Development of a new once-a-day formulation of methylphenidate (...) . www.FdaAdvisoryCommittee.com/FDC/Advisory_Committee/ U.S. FDA NDA 21-121 Concerta Medical Review. Avail at www.fda.gov/cder Wilens T, McBurnett K, Stein M, Lerner M et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. Journal of the Academy of Child and Adolescent Pyschiatry 2005; 44(10): 1015-1023. Wilens TE et al. Multisite controlled study of OROS MPH in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006; 160

2010 Therapeutics Letter

172. Should a child with ADHD and epilepsy be given Ritalin?

with epilepsy and ADHD] does [methylphenidate (MPH)compared with placebo or no MPH] increase [the number of seizures]? Clinical Scenario A 10-year-old boy with well controlled epilepsy on sodium valproate attends your clinic. On a previous clinic visit his mother complained that he was hyperactive, impulsive and could not concentrate. This was affecting his school work. You sent Conners' Questionnaires to his parents and the school, and asked the attention deficit hyperactivity disorder (ADHD) nurse (...) , may have a particularly important role, as clinician biases are unlikely to affect the rates of adverse reactions. It is also important to note that antiepileptic drugs (AEDs) can cause behavioural disturbances and doses or drug type may need to be adjusted. Editor Comment ADHD, attention deficit hyperactivity disorder; AED, antiepileptic drug; MPH, methylphenidate. Clinical Bottom Line There is no good evidence to suggest an increase in seizure frequency in a child with well controlled epilepsy

2010 BestBETS

173. Efficacy of meta-cognitive therapy for adult ADHD Full Text available with Trip Pro

Efficacy of meta-cognitive therapy for adult ADHD The authors investigated the efficacy of a 12-week manualized meta-cognitive therapy group intervention designed to enhance time management, organization, and planning in adults with attention deficit hyperactivity disorder (ADHD).Eighty-eight clinically referred adults who met DSM-IV criteria for ADHD according to clinical and structured diagnostic interviews and standardized questionnaires were stratified by ADHD medication use and otherwise (...) randomly assigned to receive meta-cognitive therapy or supportive psychotherapy in a group modality. Meta-cognitive therapy uses cognitive-behavioral principles and methods to impart skills and strategies in time management, organization, and planning and to target depressogenic and anxiogenic cognitions that undermine effective self-management. The supportive therapy condition controlled for nonspecific aspects of treatment by providing support while avoiding discussion of cognitive-behavioral

2010 EvidenceUpdates Controlled trial quality: uncertain

174. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Full Text available with Trip Pro

Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Large, rare chromosomal deletions and duplications known as copy number variants (CNVs) have been implicated in neurodevelopmental disorders similar to attention-deficit hyperactivity disorder (ADHD). We aimed to establish whether burden of CNVs was increased in ADHD, and to investigate whether identified CNVs were enriched for loci previously identified in autism (...) and schizophrenia.We undertook a genome-wide analysis of CNVs in 410 children with ADHD and 1156 unrelated ethnically matched controls from the 1958 British Birth Cohort. Children of white UK origin, aged 5-17 years, who met diagnostic criteria for ADHD or hyperkinetic disorder, but not schizophrenia and autism, were recruited from community child psychiatry and paediatric outpatient clinics. Single nucleotide polymorphisms (SNPs) were genotyped in the ADHD and control groups with two arrays; CNV analysis

2010 Lancet

175. Pharmacotherapy for treatment of attention deficits after non-progressive acquired brain injury. A systematic review Full Text available with Trip Pro

Pharmacotherapy for treatment of attention deficits after non-progressive acquired brain injury. A systematic review To systematically review the effectiveness of medications used to improve attention in people with non-progressive acquired brain injury.A systematic review.MEDLINE, EMBASE, CINALH, PUBMED and PsychINFO databases were used to identify studies published between 1987 and 2008 meeting the following criteria: studies with subjects older than 18 years; diagnosis of new onset (...) or previous acquired brain injury; medication given to improve attention and use of outcome to measure attention. Studies involving subjects in low arousal states or with neurogenerative conditions were excluded. The studies were categorized into three evidence levels: I - Randomized controlled trials; II - Prospective studies, controlled trials with methodological limitations; and III - Retrospective studies, clinical case series.Forty-seven articles were identified on initial search. Twenty-six met

2010 EvidenceUpdates

176. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy Full Text available with Trip Pro

Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy The purpose of the present study was to evaluate the efficacy of divalproex for reducing aggressive behavior among children 6 to 13 years old with attention deficit hyperactivity disorder (ADHD) and a disruptive disorder whose chronic aggression was underresponsive to a prospective psychostimulant trial.Children received open stimulant treatment during a lead-in phase that averaged 5 (...) aggression.A significantly higher proportion of children randomly assigned to divalproex met remission criteria (eight out of 14 [57%]) than those randomly assigned to placebo (two out of 13 [15%]). Divalproex was generally well tolerated.Among children with ADHD whose chronic aggressive behavior is refractory to optimized stimulant treatment, the addition of divalproex increases the likelihood that aggression will remit. A larger trial is necessary to specify with greater precision the magnitude

2010 EvidenceUpdates Controlled trial quality: uncertain

177. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day Full Text available with Trip Pro

Duration of effect of oral long-acting stimulant medications for ADHD throughout the day Duration of effect of oral long-acting stimulant medications for ADHD throughout the day Duration of effect of oral long-acting stimulant medications for ADHD throughout the day Brams M, Moon E, Pucci M, Lopez FA CRD summary This review found that most long-acting stimulants conferred benefits in populations with attention-deficit/hyperactivity disorder for up to 12 hours as measured by mathematics tests (...) . Methodological flaws and a lack of information about the quality of the studies mean that the results should be interpreted with some caution and made the reliability of the authors' conclusions unclear. Authors' objectives To determine the duration of effect of long-acting stimulant treatment in patients with attention-deficit hyperactivity disorder (ADHD) using analogue classroom protocols. Searching MEDLINE, BIOSYS and EMBASE were searched to June 2009 for relevant published studies; search terms were

2010 DARE.

178. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse

health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions RCTs examining the efficacy of bupropion in adult ADHD frequently reported (...) Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published

2010 Health Technology Assessment (HTA) Database.

179. CPG on Attention Deficit Hyperactivity Disorder (ADHD) in the Child and Adolescent Population

CPG on Attention Deficit Hyperactivity Disorder (ADHD) in the Child and Adolescent Population Clinical Practice Guideline on Attention De? cit Hyperactivity Disorder (ADHD) in Children and Adolescents CLINICAL PRACTICE GUIDELINES IN THE SPANISH NATIONAL HEALTHCARE SYSTEM MINISTRY OF HEALTH, SOCIAL POLICY , AND EQUALITY MINISTERIO DE SANIDAD, POLÍTICA SOCIAL E IGUALDADIt has been 5 years since the publication of this Clinical Practice Guideline and it is subject to updating. Clinical Practice (...) 11. Dissemination and implementation 169 12. Future research recommendations 171 It has been 5 years since the publication of this Clinical Practice Guideline and it is subject to updating. 6 CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS Appendices Appendix 1 Levels of evidence and degrees of recommendation 176 Appendix 2 Diagnostic criteria for ADHD 177 Appendix 3 Information for patients, family members and educators 180 Appendix 4

2010 GuiaSalud

180. Review: ADHD impairs quality of life, but children and young people with ADHD perceive less impairment than parents

-Research Version, the Munich Quality of Life Questionnaire for Children, the Dutch Child AZL TNO Quality of Life, the TNO AZL Child Quality of Life, the EuroQoL Five-Dimension Questionnaire, standard gamble interviews and the Global Impression of Perceived Difficulties. The only disorder-specific measure used was the ADHD Impact Module. Methods Design: Systematic review. Data sources: Ovid MEDLINE (R), Cochrane database of systematic reviews, ACP Journal Club, DARE, CCTR, CMR, HTA, NHSEED, EMBASE (...) Review: ADHD impairs quality of life, but children and young people with ADHD perceive less impairment than parents Review: ADHD impairs quality of life, but children and young people with ADHD perceive less impairment than parents | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your

2010 Evidence-Based Mental Health